文献速递区域麻醉与超声术前评估与围术期医学

静脉与周围神经右美托咪定作为外周神经阻滞辅助药疗效的系统综述

Efficacy of perineural versus intravenous dexmedetomidine as a peripheral nerve block adjunct: a systematic review.
PubMed 文献 · Reg Anesth Pain Med · 2021-05-11

中等质量证据提示,周围神经途径在感觉和运动阻滞持续时间及起效速度方面优于静脉途径,静脉途径在任何结局上均未显示优势。

要点

  • 周围神经右美托咪定较静脉途径延长感觉和运动阻滞持续时间。
  • 周围神经途径在部分试验中加快感觉和运动阻滞起效。
  • 静脉右美托咪定在任何结局上均未优于周围神经途径。

核心结论

  • 中等质量证据提示,静脉右美托咪定作为外周神经阻滞辅助药劣于周围神经右美托咪定。
  • 周围神经右美托咪定与更长的感觉和运动阻滞持续时间及更快的起效相关。

研究设计与样本

  • 阻滞类型包括上肢阻滞7项、下肢阻滞2项和躯干阻滞1项。
  • 右美托咪定剂量为预定剂量50 μg或基于体重的0.5 μg/kg至1.0 μg/kg。
  • 因临床异质性未进行定量合并,证据以系统综述形式呈现。

主要发现

  • 与静脉途径相比,周围神经右美托咪定在6项试验中的4项延长感觉阻滞持续时间。
  • 周围神经右美托咪定在7项试验中的5项延长运动阻滞持续时间。
  • 周围神经右美托咪定在6项试验中的3项加快感觉和运动阻滞起效。
  • 其余结局无差异报告,静脉右美托咪定在任何试验的任何结局上均未显示优势。

关键数值与推荐

  • 使用Cochrane偏倚风险工具和GRADE标准评估证据质量(当至少3项研究报告某结局时)。
  • 中等质量证据支持周围神经途径在阻滞持续时间和起效方面的优势。

临床怎么用

  • 临床选择右美托咪定作为外周神经阻滞辅助药时,周围神经途径可能优于静脉途径。
  • 需结合阻滞类型和患者情况个体化选择给药途径。

局限性

  • 临床多样性妨碍定量合并,证据以系统综述形式呈现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dexmedetomidine is an effective local anesthetic adjunct for peripheral nerve blocks. The intravenous route for administering dexmedetomidine has been suggested to be equally effective to the perineural route; but comparative evidence is conflicting. OBJECTIVES: This evidence-based review evaluated trials comparing the effects of intravenous to perineural dexmedetomidine on peripheral nerve block characteristics in adult surgical patients. Our primary aim was to evaluate the durations of sensory and motor blockade. Duration of analgesia, onset times of sensory and motor blockade, analgesic consumption, rest pain, and dexmedetomidine-related adverse events were evaluated as secondary outcomes. EVIDENCE REVIEW: We sought randomized trials comparing the effects of intravenous to perineural dexmedetomidine on peripheral nerve block characteristics. The Cochrane Risk of Bias tool and the Grades of Recommendation, Assessment, Development, and Evaluation criteria was used to evaluate the quality of evidence for when an outcome was reported by at least three studies. RESULTS: Ten studies compared intravenous and perineural dexmedetomidine in the setting of upper extremity blocks (seven), lower extremity blocks (two), and truncal block (one). The doses of dexmedetomidine supplementing long-acting local anesthetics varied between a predetermined dose (50 μg) and a weight-based dose (0.5 μg/kg-1.0 μg/kg). Clinical diversity precluded quantitative pooling; and evidence is presented as a systematic review. Compared with the intravenous route, moderate quality evidence found that perineural dexmedetomidine prolonged the duration of sensory blockade in four of six trials and motor blockade in five of seven trials. Perineural dexmedetomidine also hastened the onset of sensory and motor blockade in three of six trials. No differences were reported for the remaining outcomes; and intravenous dexmedetomidine was not superior for any outcome in any of the trials. CONCLUSIONS: Moderate quality evidence appears to suggest that intravenous dexmedetomidine is an inferior peripheral nerve block adjunct compared with perineural dexmedetomidine. Perineural dexmedetomidine is associated with longer durations and faster onset of sensory and motor blockade.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Hussain N, Brummett CM, Brull R, et al. Efficacy of perineural versus intravenous dexmedetomidine as a peripheral nerve block adjunct: a systematic review. Reg Anesth Pain Med. 2021. PMID: 33975918. doi:10.1136/rapm-2020-102353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。